Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025R4" target="_blank" >RIV/61988987:17110/20:A21025R4 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/20:10412223 RIV/65269705:_____/20:00072769 RIV/00179906:_____/20:10412223
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S2352302620300995" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S2352302620300995</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S2352-3026(20)30099-5" target="_blank" >10.1016/S2352-3026(20)30099-5</a>
Alternative languages
Result language
angličtina
Original language name
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Original language description
Background The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
LANCET HAEMATOLOGY
ISSN
2352-3026
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
6
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
456-468
UT code for WoS article
000537201400016
EID of the result in the Scopus database
—